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Catastrophic Antiphospholipid Syndrome
Gabriel Hocum, DO and Jeff Youker, MD
Providence St. Vincent, Internal Medicine Residency, Portland, Oregon
Catastrophic Antiphospholipid Syndrome (CAPS) is a rare and 
extreme manifestation of Antiphospholipid Syndrome (APS) 
that features widespread thrombotic disease affecting 
multiple small vessels in a short time frame. CAPS affects only 
0.8% of APS patients, but when it occurs it is has a mortality 
rate of approximately 50%.
Most of our understanding of this condition comes from retrospective analyses of patients in 
the “CAPS Registry”, which in 2016 included about 500 patients. It is more common in 
women, and the average age of onset is 38. 60% of these patients had an underlying primary 
diagnosis of APS; 30% had an associated SLE diagnosis; 65% of cases had an identifiable 
antecedent, most commonly, infection. 
Diagnostic Criteria:
1. Involvement of three or more organs, systems, and/or tissues 
2. Development of manifestations simultaneously or in less than a week
3. Presence of antiphospholipid antibodies
4. Histopathologic evidence of small vessel occlusion in at least one organ or tissue
Treatment:
1. Treatment of the inciting factor if one is identifiable (e.g. antibiotics for bacterial infection)
2. Anticoagulation, usually with heparin
3. High dose intravenous steroids 
4. Plasma exchange and/or IVIG
5. Other considerations: cyclophosphamide, rituximab, eculizumab
This case highlights the severity of the CAPS disease process, and the importance of early 
recognition and aggressive management. The primary prognostic factor for this patient, 
however, was not prompt diagnosis or treatment, but the extent of irreversible damage at 
the time of presentation. 
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A 50 year old female with SLE and APS presented with 1 month 
of cough and fatigue and 2 days of severe confusion after 
missing doses of rivaroxaban. In the ED she was intubated for 
airway protection and transferred to the ICU.
Her evaluation revealed multi-organ failure with extensive 
subacute brain infarcts, NSTEMI, severe heart failure, acute 
kidney injury, and acute on chronic anemia and 
thrombocytopenia. Her brain lesions were randomly 
distributed and could not be explained by a typical 
cardioemobolic phenomenon or global hypo-perfusion. Lab 
work revealed decreased C3 and C4, and increased anti-
cardiolipin and anti-B2-glycoprotein antibodies.
She was diagnosed with probable CAPS based on clinical 
criteria, and treated with high dose steroids, anticoagulation 
and IVIG. Her acuity prevented histopathologic confirmation of 
small vessel occlusion. Despite some signs of clinical 
improvement and successful prevention of further thrombotic 
events, she had sustained extensive irreversible neurologic 






Extensive subacute infarctions with associated petechial hemorrhage throughout the cerebral hemispheres and cerebellum
